868 abstracts found.



Results filter

Efficacy and toxicities of a reduced dose sunitinib regimen in metastatic renal cell carcinoma

Year:

Session type:

Wei Seong Ooi1, Ko Ko Lin Thaw1, Valerie Khoo1, Vanessa Khoo1, Ravindran Kanesvaran1, Alexandre Chan3, Miah Hiang Tay1, Chee Keong Toh1, Min-Han Tan1

1National Cancer Centre Singapore, Singapore, 2National Cancer Centre Singapore, Singapore


Biological properties of the novel Chk1 inhibitor SAR-020106

Year:

Session type:

Paul Eve1, Mike Walton1, Angela Hayes1, Melanie Valenti1, Alexis De Haven Brandon1, Kathy Boxall1, Wynne Aherne1, Sue Eccles1, Gary Box1, Florence Raynaud1, David Williams2, Ian Collins1, John Reader2, Michelle Garrett1

1The Institute of Cancer Research, Surrey, UK, 2Sareum Ltd, Cambridge, UK


Combined targeting of Aurora B (AZD1152) and MEK1/2 (AZD6244) kinases leads to enhancement of anti-tumour effects in vivo

Year:

Session type:

Rajesh Odedra1, Simon P Heaton2, Armelle Logie1, Elizabeth Anderson1, Paul D Smith1, Robert W Wilkinson1

1AstraZeneca Pharmaceuticals, Macclesfield, UK, 2The Institute of Cancer Research, Sutton, UK


Phase I evaluation of radioimmunotherapy with 131I-CHT25 in patients with refractory IL2-receptor-expressing lymphomas

Year:

Session type:

Richard Begent2, Christopher McNamara2, Philip Ross1, James Ritchie1

1Cancer Research UK, London, UK, 2Royal Free Hospital, London, UK


Construction and characterisation of novel fusion toxin targeted to cancer (DT-SCF)

Year:

Session type:

Sirisha Potala, Rama Verma

Indian Institute of Technology Madras, Tamil Nadu, India


A comparison of the UCLA Integrated Staging System (UISS) model and the Leibovich score in survival prediction for patients with non-metastatic clear cell renal cell carcinoma

Year:

Session type:

Tiffany Tang1, Min Tun Nay1, Myo Oo Nay1, Kamalakannan Srimalan1, Caroline Choong2, Vanessa Khoo1, Valerie Khoo1, Tsung Wen Chong2, Puay Hoon Tan2, Min-Han Tan1

1The National Cancer Centre, Singapore, 2Singapore General Hospital, Singapore


A novel role for Nutlin-3 in the mammalian DNA-damage response

Year:

Session type:

Jane Valentine, Sonia Kumar, Abdeladim Moumen

St George's Hospital, University of London, UK


A neurofuzzy model to identify insignificant prostate cancer: development and validation using the ProtecT randomised controlled trial

Year:

Session type:

James Catto1, Maysam Abbod5, Derek Linkens1, Derek Rosario1, Jenny Donovan4, David Neal3, Freddie Hamdy2

1University of Sheffield, UK, 2University of Oxford, UK, 3University of Cambridge, UK, 4University of Bristol, UK, 5Brunel University, London, UK


A two stage multicentre phase II study of Imatinib in the treatment of patients with c-kit positive metastatic uvEal Melanoma (ITEM)

Year:

Session type:

Ernie Marshall1, Carlos Escriu1, Paul Nathan4, S Danson5, M Marples6, Sarah E Coupland2, Catrin Tudur Smith3, Susanna Dodd3, Matthew Bickerstaff3, Bertil Damato2

1Clatterbridge Centre for Oncology, Merseyside, UK, 2Royal Liverpool University Hospital, UK, 3Liverpool Clinical Trials Unit, UK, 4Mount Vernon Hospital, Middlesex, UK, 5Weston Park Hospital, Sheffield, UK, 6St James University Hospital, Leeds, UK


A comparison of MicroRNA profiles in the circulating cells from men with locally confined and advanced prostate cancer

Year:

Session type:

Geetha Laxala1, Freddie Hamdy2, Stephane Larre2, James Catto1

1University of Sheffield, UK, 2University of Oxford, UK


Page 1 of 871...25...Last »